Quote:

---

CYDY announced today that Jacob Lalezari, M.D., CEO of Quest Clinical Research, Bruce Patterson, M.D., Chief Executive Officer and founder of IncellDx, a diagnostics company and an advisor to CytoDyn, and Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn, will provide a comprehensive business update.

---

Below are my main questions for the business update in order of (my) importance:

1) NP: Update on enrolled patients for COVID P2 Mild-to-Moderate
2) Dr. Lalezari (Dr. L): Status of compassionate application/approval with FDA
3) Dr. Patterson (Dr. P): When and where is the paper to be published?
4) NP: Please add some color to what happened with the BLA
submission. The communication of his has been a big mishap
5) Dr. L: When is the BTD meeting with FDA going to take place ???
6) Dr. P: Why were the Viral Plasma measurements stopped/reported until 7 days only ?
7) NP: What is the status of “old” mTNBC patients? Any more treatments initialized?
NP: Status of IND basket trial. Any developments??
9) NP: Is there any possibility of Government/private funding coming our way ??
10) NP: Update on enrolled patients of COVID P2b/3 Severe trial